Advertisement

Drugs & Aging

, Volume 5, Issue 2, pp 116–126 | Cite as

Pharmacological Manipulations of the α2-Noradrenergic System

Effects on Cognition
  • Jennifer T. Coull
Review Article Clinical Pharmacology

Summary

Electrophysiological and neurosurgical lesion studies with experimental animals have implicated the ascending dorsal noradrenergic bundle of the locus coeruleus system in cognitive process such as memory, learning and selective attention. However, it has also been suggested that noradrenaline (norepinephrine) is crucial in certain cognitive functions associated with the frontal lobes, particularly the prevention of distractibility by irrelevant stimuli. The α2-receptors of the prefrontal cortex appear to be of particular importance in this respect. Studies with humans and experimental primates provide substantial support for this view.

The aged primate brain is prone to degeneration of the locus coeruleus, as well as profound catecholamine depletion in the prefrontal cortex, and so is ideal for psychopharmacological investigation of the role of noradrenaline in frontal lobe function. Elderly monkeys show deficits in performance of the delayed response task, which can be reversed directly by both the mixed α1/(α2-agonist clonidine, the more specific α2-agonist guanfacine and also, indirectly, by the α2-antagonist yohimbine. It is suggested that these results can be explained by an attenuation of the distracting properties of irrelevant stimuli following stimulation of noradrenergic activity. Conversely, distractibility is magnified whenever noradrenergic activity is reduced. This is supported by similar findings in psychopharmacological studies of healthy humans. The exception to this is when the locus coeruleus is likely to be firing, e.g. in times of stress or when novel stimuli are encountered. Clonidine attenuates locus coeruleus firing on such occasions, and so counteracts any beneficial (or deleterious) effects of stress on task performance.

α2-Adrenoceptor agents have little therapeutic value in patients with dementia of the Alzheimer’s type. However, they may have some clinical use in patients who have a cognitive symptomatology similar to that of patients who have received neurosurgical excisions to the frontal lobes, e.g. deficits in working memory, executive function or focused attention, with relative sparing of episodic short term memory. Patients with Korsakoff’s disease, attention deficit disorder or schizophrenia may benefit from treatment with α2-agents. In particular, idazoxan has putative therapeutic effects in patients with a neurodegenerative disorder, namely dementia of frontal type.

Keywords

Clonidine Locus Coeruleus Guanfacine Idazoxan Frontal Lobe Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Robbins TW, Everitt BJ. Functional studies of the central catecholamines. Int Rev Neurobiol 1982; 23: 303–65PubMedCrossRefGoogle Scholar
  2. 2.
    Crow TJ. Cortical synapses and reinforcement. Nature 1968; 219: 736–7PubMedCrossRefGoogle Scholar
  3. 3.
    Kety SS. The biogenic amines and the central nervous system: their possible roles in arousal, emotion and learning. In: Schmidt FO, editor. The neurosciences, second study program. New York: Rockefeller University Press, 1970: 324–36Google Scholar
  4. 4.
    Mason ST, Iversen SD. Theories of dorsal bundle extinction effect. Br Res Rev 1979; 1: 107–37CrossRefGoogle Scholar
  5. 5.
    Arnsten AFT, Goldman-Rakic PS. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985; 230: 1273–6PubMedCrossRefGoogle Scholar
  6. 6.
    Arnsten AFT, Contant TA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berl) 1992; 108: 159–69CrossRefGoogle Scholar
  7. 7.
    Coull JT, Middleton HC, Sahakian BJ, et al. The mixed α12 agonist clonidine has specific and non-sedative effects on tests of frontal lobe function in man. Soc Neurosci Abstracts 1993; 19(1): abstract 233.4Google Scholar
  8. 8.
    Sahakian BJ, Coull JT, Hodges JR. Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type. J Neurol Neurosurg Psychiatry 1994; 57: 120–1PubMedCrossRefGoogle Scholar
  9. 9.
    Foote SL, Bloom FE, Aston-Jones G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificty. Physiol Rev 1983; 63: 844–914PubMedGoogle Scholar
  10. 10.
    Fillenz M. Noradrenergic neurons. Cambridge: Cambridge University Press, 1990Google Scholar
  11. 11.
    Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand 1971; 367 Suppl.: 1–49Google Scholar
  12. 12.
    Rang HP, Dale MM. Pharmacology. Edinburgh: Churchill Livingstone, 1987: 449Google Scholar
  13. 13.
    Stein L. Chemistry of reward and punishment. In: Efron DH, editor. Psychopharmacology: a review of progress 1957–1967. Washington DC: US Government Printing Office, 1968: 105–23Google Scholar
  14. 14.
    Aston-Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggest a role in vigilance. In: Barnes CD, Pompeiano O, editors. Progress in brain research 88. Amsterdam: Elsevier Science Publishers, 1991: 501–20Google Scholar
  15. 15.
    Carli M, Robbins TW, Evenden JL, et al. Effects of lesions to ascending noradrenergic neurons on performance of a 5-choice serial reaction time task in rats: implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 1983; 9: 361–80PubMedCrossRefGoogle Scholar
  16. 16.
    Cole BJ, Robbins TW. Forebrain norepinephrine: role in controlled information processing in the rat. Neuropsychopharmacology 1992; 7: 129–42PubMedGoogle Scholar
  17. 17.
    Foote SL, Aston-Jones G, Bloom FE. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci U S A 1975; 77: 3033–7CrossRefGoogle Scholar
  18. 18.
    Kasamatsu T. Neuronal plasticity maintained by the central norepinephrine system in the cat visual cortex. In: Sprague JM, Epstein AN, editors. Progress in psychobiology and physiological psychology, volume 10. New York: Academic Press, 1983: 1–112Google Scholar
  19. 19.
    Glue P, Wilson S, Lawson C, et al. Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. J Psychopharmacology 1991; 5: 396–403CrossRefGoogle Scholar
  20. 20.
    Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 1975; 92: 291–306PubMedCrossRefGoogle Scholar
  21. 21.
    Everitt BJ, Robbins TW, Gaskin M, et al. The effects of lesions to ascending noradrenergic neurons on discrimination learning and performance. Neuroscience 1983; 10: 397–410PubMedCrossRefGoogle Scholar
  22. 22.
    Robbins TW. Cortical noradrenaline, attention and arousal. Psycho1 Med 1984; 14: 13–21CrossRefGoogle Scholar
  23. 23.
    Arnsten AFT, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfecine improves memory in aged monkeys without sedative or hypotensive side-effects. J Neurosci 1988; 8: 4287–98PubMedGoogle Scholar
  24. 24.
    Arnsten AFT, Cai JX. Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 1994; 14: 597–603CrossRefGoogle Scholar
  25. 25.
    Ong ML, Ball SG, Vaughn PFT. Regulation of noradrenaline release from rat occipital cortex tissue chops by alpha-2-adrenergic agents. J Neurochem 1991; 56: 1387–93PubMedCrossRefGoogle Scholar
  26. 26.
    Starke K, Borowski E, Endo T. Preferential blockade of presynaptic alpha-receptors by yohimbine. Eur J Pharmacol 1975; 279: 53–60Google Scholar
  27. 27.
    Frith CD, Dowdy J, Ferrier IN, et al. Selective impairment of paired associate learning after administration of a centrally-acting adrenergic agonist (clonidine). Psychopharmacology (Berl) 1985; 87: 490–3CrossRefGoogle Scholar
  28. 28.
    Clark CR, Geffen GM, Geffen LB. Catecholamines and the covert orientation of attention in humans. Neuropsychologia 1989; 27: 131–9PubMedCrossRefGoogle Scholar
  29. 29.
    Posner MI. Orienting of attention. Q J Exp Psychol 1980; 32: 3–25PubMedCrossRefGoogle Scholar
  30. 30.
    Smith AP, Wilson SJ, Glue P, et al. The effects and after effects of the α2-adrenoceptor antagonist idazoxan on mood, memory and attention in normal volunteers. J Psychopharmacol 1992; 6: 376–81PubMedCrossRefGoogle Scholar
  31. 31.
    Sirvio J, Jakala P, Mazurkiewicz M, et al. Dose- and parameter-dependant effects of atipamezole, an α2 antagonist, on the performance of rats in a five-choice serial reaction time task. Pharmacol Bioch Behav 1993; 45: 123–9CrossRefGoogle Scholar
  32. 32.
    Woods DL, Knight RT. Electrophysiologic evidence of increased distractability after dorsolateral prefrontal lesions. Neurology 1986; 36: 212–6PubMedCrossRefGoogle Scholar
  33. 33.
    Thomas DN, Nutt DJ, Holman RB. Effects of acute and chronic electroconvulsive shock on noradrenaline release in the rat hippocampus and frontal cortex. Br J Pharmacol 1992; 106: 430–4PubMedCrossRefGoogle Scholar
  34. 34.
    Brown RM, Crane AM, Goldman PS. Regional distribution of monoamines in the cerebral cortex and subcortical structures on the rhesus monkey: concentrations in vivo synthesis rates. Brain Res 1979; 168: 133–50PubMedCrossRefGoogle Scholar
  35. 35.
    Levitt P, Rakic P, Goldman-Rakic PS. Region-specific distribution of catecholamine afferents in primate cerebral cortex: a fluorescence histochemical analysis. J Comp Neurol 1984; 227: 23–36PubMedCrossRefGoogle Scholar
  36. 36.
    Goldman-Rakic PS, Lidow MS, Gallagher DW. Overlap of dopaminergic, adrenergic and serotonergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci 1990; 10: 2125–38PubMedGoogle Scholar
  37. 37.
    Goldman-Rakic PS. Circuitry of the primate prefrontal cortex and the regulation of behaviour by representational memory. In: Plum F, editor. Handbook of physiology: the nervous system of the brain, higher functions of the brain, section 1: 5 (1). Bethesda: American Physiological Society, 1987: 373–417Google Scholar
  38. 38.
    Brozoski TJ, Brown R, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science 1979; 205: 929–31PubMedCrossRefGoogle Scholar
  39. 39.
    Vijayashankar N, Brody H. A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J Neuropathol Exp Neurol 1979; 38: 490–7PubMedCrossRefGoogle Scholar
  40. 40.
    Goldman-Rakic PS, Brown RM. Regional changes of mono-amines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981; 6: 177–87PubMedCrossRefGoogle Scholar
  41. 41.
    Bartus RT, Dean RL. Recent memory in aged non-human primates: hypersensitivity to visual interference during retention. Exp Aging Res 1979; 5: 385–400PubMedCrossRefGoogle Scholar
  42. 42.
    Hoyer WJ, Rebok GW, Sved SM. Effects of varying irrelevant information on adult age differences in problem solving. J Gerontol 1979; 34: 553–60PubMedGoogle Scholar
  43. 43.
    Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82: 147–50PubMedCrossRefGoogle Scholar
  44. 44.
    Jones GMM, Sahakian BJ, Levy R, et al. Effects of subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology 1992; 108: 485–94PubMedCrossRefGoogle Scholar
  45. 45.
    Terry AV, Jackson WJ, Buccafusco JJ. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cerebral cortex 1993; 3: 304–12PubMedCrossRefGoogle Scholar
  46. 46.
    Joyce EM, Robbins TW. Frontal lobe function in Korsakoff and non-Korsakoff alcoholics: planning and spatial working memory. Neuropsychologia 1991; 29: 709–23PubMedCrossRefGoogle Scholar
  47. 47.
    Shallice T. Specific impairments in planning. Phil Trans R Soc Lond 1982; B298: 199–209Google Scholar
  48. 48.
    Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in Man. Neuropsychologia 1990; 29: 993–1000CrossRefGoogle Scholar
  49. 49.
    McEntee WJ, Mair RG. Memory enhancement in Korsakoff’s psychosis by clonidine: further evidence for a noradrenergic deficit. Ann Neurol 1980; 7: 466–70PubMedCrossRefGoogle Scholar
  50. 50.
    Mair RG, McEntee WJ. Cognitive enhancement in Korsakoff’s psychosis by clonidine: acomparison with L-Dopa and ephedrine. Psychopharmacology 1986; 84: 58–63Google Scholar
  51. 51.
    Mair RG, McEntee WJ, Zatorre RJ. Monoamine activity correlates with psychometric deficits in Korsakoff’s disease. Behav Brain Res 1985; 15: 247–54PubMedCrossRefGoogle Scholar
  52. 52.
    McEntee WJ, Mair RG, Langlais PJ. Neurochemical specificity of learning: dopamine and motor learning. Yale J Biol Med 1987; 60: 187–93PubMedGoogle Scholar
  53. 53.
    O’Carroll RE, Moffoot A, Ebmeier KP, et al. Korsakoff’s syndrome, cognition and clonidine. Psychol Med 1993; 23: 341–7PubMedCrossRefGoogle Scholar
  54. 54.
    Moffoot, O’Carroll RE, Murray C, et al. Clonidine infusion increases uptake of 99mTc-exametazine in anterior cingulate cortex in Korsakoff’s psychosis. Psychol Med 1994; 24: 53–61PubMedCrossRefGoogle Scholar
  55. 55.
    Benton AL. Differential effects of frontal lobe disease. Neuropsychologia 1968; 6: 53–60CrossRefGoogle Scholar
  56. 56.
    Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adlesc Psychiatry 1985; 24: 617–29CrossRefGoogle Scholar
  57. 57.
    Mair RG, McEntee WJ, Zatorre RJ. Monoamine activity correlates with psychometric deficits in Korsakoffs disease. Behav Brain Res 1985; 15: 247–54PubMedCrossRefGoogle Scholar
  58. 57.
    Weinberger DR. Schizophrenia and the frontal lobe. Trends Neurosci 1988: 367–70Google Scholar
  59. 58.
    Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19: 371–429PubMedGoogle Scholar
  60. 59.
    Van Kammen DP. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychol Med 1991: 21: 881–95PubMedCrossRefGoogle Scholar
  61. 60.
    Van Kammen DP, Peters J, van Kammen WB, et al. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 1989; 26: 176–88PubMedCrossRefGoogle Scholar
  62. 61.
    Van Kammen DP, Peters J, Yao J, et al. Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 1990; 47: 161–8PubMedCrossRefGoogle Scholar
  63. 62.
    Van Kammen DP, Peters JL, van Kammen WB, et al. Clonidine treatment of schizophrenia: can we predict treatment response? Psychiatry Res 1989; 27: 297–311PubMedCrossRefGoogle Scholar
  64. 63.
    Litman RE, Hong WW, Weissman EM, et al. Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 1993; 13: 264–7PubMedCrossRefGoogle Scholar
  65. 64.
    Fields RB, van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independantly from change in psychosis: preliminary findings. Schizophr Res 1988; 1: 417–23PubMedCrossRefGoogle Scholar
  66. 65.
    Krystal JH, McDougle CJ, Woods SW, et al. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology 1992; 108: 313–9PubMedCrossRefGoogle Scholar
  67. 66.
    Brun A, Englund B, Gustafson L, et al. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416–8CrossRefGoogle Scholar
  68. 67.
    Miller BL, Cummings JL, Villaneuva-Meyer J, et al. Frontal lobe degeneration: clinical, neuropsychological and SPECT characteristics. Neurology 1991; 41: 1374–82PubMedCrossRefGoogle Scholar
  69. 68.
    Coull JT, Charlesworth GM, Hodges JR, et al. Sustained attention deficits in patients with frontal lobe excisions or dementia of frontal type. In preparationGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Jennifer T. Coull
    • 1
  1. 1.Department of Experimental PsychologyUniversity of CambridgeCambridgeEngland

Personalised recommendations